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Background:  ST-elevation myocardial infarction (STEMI) is characterized by acute plaque rupture compromising blood flow at the epicardial 
and microvascular levels. Endothelin (ET) is a mediator of microvascular dysfunction and adverse cardiac remodeling. We hypothesized that 
administration of an ET-A receptor antagonist (BQ-123) may protect microvascular function from the ET-dependent injury. The objective of our study 
was to assess the safety and efficacy of BQ-123 in AMI.
Methods:  Patients with posterior-wall STEMI (n=57) were randomly assigned to receive intravenous BQ-123 at 400nmol/minute or placebo over 
60 minutes, starting immediately prior to primary percutaneous coronary intervention (PCI). The primary study endpoint was microvascular perfusion 
assessed by first-pass perfusion cardiac magnetic resonance imaging (MRI).
Results:  In patients randomized to BQ-123 we observed shorter microvessel perfusion delays 6 days after PCI (1.8 (0.7-3.4)s versus 3.3 (2.3-5.4)
s in placebo-treated patients, p=0.005). In the treatment group all patients reached a final TIMI III coronary flow. All patients were alive at 30 days.
Conclusion: Short-term administration of a selective ET-A receptor blocker during primary PCI is safe and improves tissue-level perfusion in 
patients with STEMI.
